market cap mystery, page-4

thanks GKM

I am definitely new to the Biotech space, so this is all good reading. I just think I am incredibly lucky that I invested in TIS within the last year, as opposed to 5 or 6 years ago

Can you also answer why the focus on the US (as presumably the largest market for particularly diabetic uclers) is behind Europe? is it because of the regulatory difficulty, or does having European approval make US approval easier?